Leeloo (Ethinylestradiol, Levonorgestrel)

Leeloo, a combined oral contraceptive, is used within the hormonal birth‑control pathway to prevent pregnancy and manage related menstrual conditions.

• Contraception: Prevents pregnancy by suppressing ovulation, thickening cervical mucus, and altering the endometrium.
• Menstrual cycle regulation: Provides predictable withdrawal bleeding and reduces irregular menstrual bleeding.
• Acne treatment: Improves acne vulgaris by reducing androgenic activity on the skin.

• Leeloo combines ethinylestradiol, a synthetic estrogen, with levonorgestrel, a progestogenic agent. The estrogen component stabilizes the endometrial lining while the progestin suppresses the hypothalamic‑pituitary‑ovarian axis, preventing the luteinizing hormone surge required for ovulation. Together they thicken cervical mucus and induce endometrial changes that inhibit implantation. Ethinylestradiol binds to estrogen receptors, providing negative feedback on follicle‑stimulating hormone, while levonorgestrel binds to progesterone receptors, inhibiting follicular growth and luteal phase support.

Leeloo may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring early in treatment.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Headache: mild to moderate headaches.
• Spotting between periods: irregular light bleeding.
• Mood changes: mild fluctuations in mood or irritability.
• Weight gain: slight increase in body weight.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Stroke or myocardial infarction: rare cardiovascular events.
• Severe hypertension: sudden high blood pressure.
• Liver tumor: hepatic adenoma or carcinoma.
• Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Leeloo, clinicians should evaluate several safety considerations.

• Pregnancy contraindication: Not for use in pregnant women; must be discontinued if pregnancy occurs.
• Smoking restriction: Women over 35 who smoke should avoid use due to increased thrombotic risk.
• Cardiovascular disease: Assess history of thromboembolism, stroke, or myocardial infarction before initiation.
• Liver dysfunction: Use with caution in patients with active liver disease.
• Migraine with aura: Contraindicated in patients experiencing migraine with visual aura.
• Drug interactions: Review concomitant medications that may affect hormonal efficacy.
• Store at below 25°C: keep in the original pack, protect from moisture.

Leeloo can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): reduce hormone levels, decreasing contraceptive efficacy.
• Rifampin and other strong inducers: markedly lower ethinylestradiol concentrations.
• Griseofulvin: may diminish contraceptive protection.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole, itraconazole): increase hormone levels, raising risk of side effects.
• SSRIs (e.g., fluoxetine, sertraline): may elevate plasma concentrations of ethinylestradiol.
• St. John’s wort: herbal inducer that can lower contraceptive effectiveness.